Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Related GHDX
Genomic Health's Oncotype DX Redefines Breast Cancer Therapy - Analyst Blog
Genomic Health Up on Fresh Cancer Study Data - Analyst Blog

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (GHDX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free